High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (≥65 years) myeloma patients: Comparison with younger patients treated on the same protocol

Bone Marrow Transplantation

Volumn 37, Issue 10, 2006, Pages 917-922

  Jantunen, Esa ^a   Kuittinen, T ^a   Penttila K ^a   Lehtonen, P ^a   Mahlamaki E ^a   Nousiainen, T ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

ASCT; Elderly patients; Multiple myeloma; Outcome; Toxicity

Indexed keywords

ALPHA INTERFERON; AMIFOSTINE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUCONAZOLE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MELPHALAN; MESNA; VINCRISTINE;

ADULT; AGED; ALPHA HEMOLYTIC STREPTOCOCCUS; APHERESIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL PROTOCOL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ELDERLY CARE; ERYTHROCYTE TRANSFUSION; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL DISEASE; GRAFT INFECTION; GRAFT VERSUS HOST REACTION; HEART DISEASE; HUMAN; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; MOUTH DISEASE; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; OVERALL SURVIVAL; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STEM CELL MOBILIZATION; THROMBOCYTE TRANSFUSION; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

ADULT; AGE FACTORS; AGED; DISEASE-FREE SURVIVAL; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; MYELOABLATIVE AGONISTS; STEM CELL TRANSPLANTATION; STEM CELLS;

EID: 33646913813     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705360     Document Type: Article

References (28)

1. Clavio M, Casciaro S, Gatti AM, Spriano L, Bonanni F, Poggi A et al. Multiple myeloma in the elderly: Clinical features and response to treatment in 113 patients. Haematologica 1996; 81: 238-244.
2. Riccardi A, Mora O, Brugnatelli S, Tinelli C, Spanedda R, De Paoli A et al. Relevance of age on survival of 341 patients with multiple myeloma treated with conventional chemotherapy: Updated results of the MM87 prospective randomized protocol. Br J Cancer 1998; 77: 485-491.
3. Rodon P, Linsassier C, Gauvain JB, Benboubker L, Goupille P, Maigre M et al. Multiple myeloma in elderly patients: Presenting features and outcome. Eur J Haematol 2001; 66: 11-17.
4. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91-97.
5. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. for Medical Research Council Unit Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
6. Barlogie B, Jagannath S, Vesole DH, Naucke S, Cheson B, Mattox S et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 99: 789-793.
7. Lenhoff S, Hjorth M, Holmberg E, Turesseon I, Westin J, Nielsen JL et al. for the Nordic Myeloma Study Group. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: A population-based study. Blood 2000; 95: 7-11.
8. Sirohi B, Powles R, Treleaven J, Mainwaring P, Kulkarni S, Pandha H et al. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transplant 2000; 25: 533-539.
9. Badros A, Barlogie B, Siegel E, Morris C, Desikan R, Zangari M et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 2001; 114: 600-607.
10. Reece DE, Bredeson C, Perez WS, Jagannath S, Zhang MJ, Ballen KK et al. Autologous stem cell transplantation in multiple myeloma patients < 60 vs ≥ 60 years of age. Bone Marrow Transplant 2003; 32: 1135-1143.
11. 2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomised trial. Blood 2002; 99: 731-735.
12. Palumbo A, Triolo S, Argentino C, Bringhen S, Dominietto A, Rus C et al. Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. Blood 1999; 94: 1248-1253.
13. Samuels BL, Bitran JD. High-dose intravenous melphalan: A review. J Clin Oncol 1995; 13: 1786-1799.
14. 2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma. Bone Marrow Transplant 1999; 23: 1003-1006.
15. Jantunen E, Putkonen M, Nousiainen T, Pelliniemi T-T, Mahlamäki E, Remes K. Low-dose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilisation in patients with multiple myeloma. Bone Marrow Transplant 2003; 31: 347-351.
16. Jantunen E, Kuittinen T, Nousiainen T. A pilot study on feasibility and efficacy of amifostine preceding high-dose melphalan with autologous stem cell support in myeloma patients. Leuk Lymphoma 2002; 43: 1961-1965.
17. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
18. Blade J, Samson D, Reece D, Apperley J, Björkstrand B, Gahrton G et al. for the Myeloma Subcommittee of the EBMT. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998; 102: 1115-1123.
19. Siegel DS, Desikan KR, Mehta J, Singhal S, Fassas A, Munshi N et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 1999; 93: 51-54.
20. Guba SC, Vesole DH, Jagannath S, Bracy D, Barlogie B, Tricot G. Peripheral stem cell mobilization and engraftment in patients over 60 years of age. Bone Marrow Transplant 1997; 20: 1-3.
21. Wahlin A, Eriksson M, Hultdin M. Relation between harvest success and outcome after autologous peripheral blood stem cell transplantation in multiple myeloma. Eur J Haematol 2004; 73: 263-268.
22. Thieblemont C, Dumontet C, Saad H, Roch N, Bouafia F, Amaud P et al. Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma. Bone Marrow Transplant 2002; 30: 769-775.
23. Spencer A, Horvath N, Gibson J, Prince HM, Herrmann R, Bashford J et al. Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplant 2005; 35: 971-977.
24. Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004; 351: 2590-2598.
25. Terpos E, Apperley JF, Samson D, Giles C, Crawley C, Kanfer E et al. Autologous stem cell transplantation in multiple myeloma: Improved survival in non-secretory myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single centre experience in 127 patients. Bone Marrow Transplant 2003; 31: 163-170.
26. Krejci M, Buchler T, Hajek R, Svobodnik A, Krivanova A, Pour L et al. Prognostic factors for survival after autologous transplantation: A single centre experience in 133 multiple myeloma patients. Bone Marrow Transplant 2005; 35: 159-164.
27. Sirohi B, Powles R, Mehta J, Rudin C, Kulkarni S, Horton C et al. An elective single autograft with high-dose melphalan: Single-center analysis of 451 patients. Bone Marrow Transplant 2005; 36: 19-24.
28. Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Renald M et al. Major superiority of melphalan-prednisone (MP) + thalidomide (Tha1) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. Blood 2005; 106 230a (abstract 780).